<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200108046050N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-07-16</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of anti inflammatory diet on Patients with oral Lichen Planus</public_title>
      <acronym></acronym>
      <scientific_title>Effect of anti inflammatory diet on clinical symptoms of Patients with oral Lichen Planus : Randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/91589</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Participants will be assigned to two intervention and control groups using a gender-stratified block randomization. Participants will first be divided into two groups: male and female. Then, within each group, they will be assigned to two groups using random blocks of variable size (4 and 6) and a ratio of 1:1. The randomization sequence will be generated by computer software. For allocation concealment, the method of sealed opaque envelopes which are numbered sequentially will be used. In this method, each random sequence is recorded on a card. Finally, the lids of the letter envelopes will be glued and placed inside a box. At the beginning of the registration of participants, according to the order of entry of eligible participants to study, one of the envelopes will be opened in order and the assigned group of the participant will be revealed, Blinding description: The outcome assessor who will examine the patients will be blinded to the patient grouping and will record the clinical data in code form.</study_design>
      <phase>3</phase>
      <hc_freetext>oral lichen planus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Recipient of anti-inflammatory diet + routine treatment (Corticosteroid mouthwash). The intervention group will follow a standardized anti-inflammatory diet for 8 weeks. This diet is based on the principles of the Mediterranean-DASH modified diet and includes quantitative guidelines, a list of allowed/not allowed foods, and a weekly schedule. Participants must meet the following daily goals: 1. Fruits and vegetables at least: 5 units per day each unit = 80 g Minimum combination: three units of vegetables and 2 units of fruit 2. Whole grains at least: 3 units per day each unit: 1 slice of wholemeal bread (30 g) or ½ cup of rice 3. Chicken and fish and omega-3 at least: 2 servings per week (150–200 g per serving) 4. Oils Extra virgin olive oil: at least 2 tablespoons per day Prohibited: trans and industrial frying oils 5. Nuts and seeds 30 g per day (almonds, walnuts, hazelnuts) 6. Dairy 1–2 servings per day (preferably low-fat and without added sugar) Participants should minimize their intake of: Simple sugars &lt;5% of daily calories, sugary drinks 0 to a maximum of 1 serving per week Fast food, maximum of 1 serving per month Processed meat, completely prohibited Red meat ≤ 1 serving per week (100–120 g) Fried foods, maximum of 1 serving per week Education and supportive intervention: In the initial education session, the principles of the anti-inflammatory diet will be taught and a list of allowed/not allowed foods will be given to patients in writing. A food portion size guide and a sample weekly meal plan will also be given to patients. To reduce implementation errors, a dietitian will be responsible for supervising patient education and monitoring their adherence. All recommendations will be standardized and uniform. Adherence to the intervention: A participant will be considered “adherent” when they meet at least 80% of the daily dietary goals. A phone call will be made every two weeks to monitor patient adherence. Intervention 2: Control group: Recipient of routine treatment (Corticosteroid mouthwash). Patients will use a full spoon of mouthwash containing 15 betamethasone ampules in Almg syrup every 8 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The main outcomes of the study, including clinical scores and pain scores,  in two groups and three time intervals will be published.

When:
Access period starts 6 months after the results are published

To whom:
Researchers working in academic and scientific institutes, doctors and dentists

Conditions:
Use of the data for further research or meta analysis is permitted.

Where to obtain:
Katayoun Katebi 00984133355965 Department of oral medicine, Tabriz faculty of dentistry katebik@tbzmed.ac.ir

How to obtain:
The applicant sends their request via email along with their introduction, and the information and data are sent to their email after reviewing their profile.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Katayoun Katebi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Oral medicine department,  faculty of Dentistry, Tabriz university of medical sciences, Golgasht street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 41 3335 6955</telephone>
        <email>katebik@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Katayoun Katebi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Oral medicine department,  faculty of Dentistry, Tabriz university of medical sciences, Golgasht street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 41 3335 6955</telephone>
        <email>katebik@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Definitive diagnosis of OLP based on clinical and histopathological criteria
Age 18 to 65 years
Presence of symptomatic erosive and ulcerative lesions
Ability to adhere to diet
Involvement of lesions in buccal mucosa, anterior two-thirds of tongue, labial mucosa, gingiva, and hard palate (where mouthwash can come into contact with them)
Disease severity based on Thongprasom Score grade 4 and 3</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Taking immunosuppressive medications
Having systemic diseases including diabetes, high blood pressure, cardiovascular and metabolic diseases, inflammatory bowel diseases
Pregnancy or breastfeeding
Consumption of alcohol or smoking
On a vegetarian or other diet
Presence of lesions in the pharynx, soft palate and back of the tongue that require systemic treatment due to lack of mouthwash contact</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L43</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lichen planus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Recipient of anti-inflammatory diet + routine treatment (Corticosteroid mouthwash). The intervention group will follow a standardized anti-inflammatory diet for 8 weeks. This diet is based on the principles of the Mediterranean-DASH modified diet and includes quantitative guidelines, a list of allowed/not allowed foods, and a weekly schedule. Participants must meet the following daily goals: 1. Fruits and vegetables at least: 5 units per day each unit = 80 g Minimum combination: three units of vegetables and 2 units of fruit 2. Whole grains at least: 3 units per day each unit: 1 slice of wholemeal bread (30 g) or ½ cup of rice 3. Chicken and fish and omega-3 at least: 2 servings per week (150–200 g per serving) 4. Oils Extra virgin olive oil: at least 2 tablespoons per day Prohibited: trans and industrial frying oils 5. Nuts and seeds 30 g per day (almonds, walnuts, hazelnuts) 6. Dairy 1–2 servings per day (preferably low-fat and without added sugar) Participants should minimize their intake of: Simple sugars &lt;5% of daily calories, sugary drinks 0 to a maximum of 1 serving per week Fast food, maximum of 1 serving per month Processed meat, completely prohibited Red meat ≤ 1 serving per week (100–120 g) Fried foods, maximum of 1 serving per week Education and supportive intervention: In the initial education session, the principles of the anti-inflammatory diet will be taught and a list of allowed/not allowed foods will be given to patients in writing. A food portion size guide and a sample weekly meal plan will also be given to patients. To reduce implementation errors, a dietitian will be responsible for supervising patient education and monitoring their adherence. All recommendations will be standardized and uniform. Adherence to the intervention: A participant will be considered “adherent” when they meet at least 80% of the daily dietary goals. A phone call will be made every two weeks to monitor patient adherence.</i_keyword>
      <i_keyword>Control group: Recipient of routine treatment (Corticosteroid mouthwash). Patients will use a full spoon of mouthwash containing 15 betamethasone ampules in Almg syrup every 8 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Clinical score based on Thongprasom scoring system. Timepoint: Clinical score measurement at the beginning of the study (before the intervention) and 4, 8 weeks after starting routine medication and anti-inflammatory diet. Method of measurement: The largest lesion in the oral cavity is selected and its largest diameter is recorded using a sterile surgical ruler. The scoring method is as follows: Score 0: No lesion. Score 1: White striae with erythematous area &lt; 1 cm2. Score 2: White striae with erythematous area &gt; 1 cm2. Score 3: White striae with erosive area &lt; 1 cm2. Score 4: White striae with erosive area &gt; 1 cm2.</prim_outcome>
      <prim_outcome>Pain level based on visual analogue scale. Timepoint: Pain level measurement at the beginning of the study (before the intervention) and 4, 8 weeks after starting routine medication and anti-inflammatory diet. Method of measurement: Patients will be asked to mark a 10 cm line with the left end representing no pain and the right end representing the most severe pain possible.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-06-22</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Tabriz faculty of dentistry, Golghasht street Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
